DVAX Relative Valuation
DVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DVAX is overvalued; if below, it's undervalued.
Historical Valuation
Dynavax Technologies Corp (DVAX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.56 is considered Undervalued compared with the five-year average of -6.53. The fair price of Dynavax Technologies Corp (DVAX) is between 22928.27 to 22941.09 according to relative valuation methord. Compared to the current price of 10.30 USD , Dynavax Technologies Corp is Undervalued By 99.96%.
Relative Value
Fair Zone
22928.27-22941.09
Current Price：10.30
99.96%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.39
P/B
Median3y
2.72
Median5y
6.91
4.38
FCF Yield
Median3y
5.56
Median5y
3.71
Competitors Valuation Multiple
The average P/S ratio for DVAX's competitors is 34458.22, providing a benchmark for relative valuation. Dynavax Technologies Corp Corp (DVAX) exhibits a P/S ratio of 3.56, which is -99.99% above the industry average. Given its robust revenue growth of 34.21%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Dynavax Technologies Corp (DVAX) currently overvalued or undervalued?
What is Dynavax Technologies Corp (DVAX) fair value?
How does DVAX's valuation metrics compare to the industry average?
What is the current P/B ratio for Dynavax Technologies Corp (DVAX) as of Jul 08 2025?
What is the current FCF Yield for Dynavax Technologies Corp (DVAX) as of Jul 08 2025?
What is the current Forward P/E ratio for Dynavax Technologies Corp (DVAX) as of Jul 08 2025?